<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699621</url>
  </required_header>
  <id_info>
    <org_study_id>A-1 EUDRACT 2007-006206-24</org_study_id>
    <nct_id>NCT00699621</nct_id>
  </id_info>
  <brief_title>Platelet Transfusion in Acute Intracerebral Hemorrhage</brief_title>
  <official_title>Platelet Transfusion in Acute Primary Intracerebral Hemorrhage for Patients on Platelet Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To prove whether use of antiplatelet agents results into a rapid enlargement of hematoma
           after onset of acute intracerebral hemorrhage.

        -  To prove the efficacy and safety of platelet transfusion for prevention of hematoma
           growth in patients who were stricken by acute intracerebral hemorrhage while being on
           antiplatelet medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Hematoma growth is a well-known powerful determinant of mortality and poor outcome after
           intracerebral hemorrhage.

        -  Some observations suggest that previous use of antiplatelet agents associates with rapid
           hematoma enlargement and poor outcome after cerebral hemorrhage.

        -  Immediate platelet transfusion for such patients may prevent hematoma growth but also
           cause thromboembolic complications.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematoma growth within 24 h measured as increase in hematoma volume observed by head CT</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glasgow Outcome Score</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death occurring within the treatment period</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to any cause occurring within the treatment period</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial infarction</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous thromboembolism</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Platelet transfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No platelet transfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>platelets</intervention_name>
    <description>Four units of fresh platelets will be infused immediately</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  being on either aspirin or clopidogrel or a combination of aspirin and dipyridamole

          -  acute primary ICH

          -  &gt; 17 years

          -  admitted within 6 h after onset of ICH

          -  ICH score &lt; 4

        Exclusion Criteria:

          -  other type of ICH than acute primary intracerebral hemorrhage

          -  patients who need neurosurgery

          -  life expectancy less than 3 months due to comorbid disorders

          -  confirmed malignant disease (cancer)

          -  confirmed acute myocardial infarction

          -  hepatitis and/liver cirrhosis

          -  renal failure

          -  infectious disease (HIV, endocarditis etc.)

          -  current or previous hematologic disease

          -  women of childbearing age if pregnant

          -  participation in another study within the preceding 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matti E Hillbom, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oulu University Central Hospital, Department of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seppo S Juvela, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Turku University Central Hospital, Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lauri Soinne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Department of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olli Häppölä, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aimo Rissanen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keski-Suomen Keskussairaala</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matti E Hillbom, MD, PhD</last_name>
    <phone>358-8-315-4518</phone>
    <email>matti.hillbom@oulu.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juha T Huhtakangas, MD</last_name>
    <phone>358-8-315-4032</phone>
    <email>juha.huhtakangas@ppshp.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90029 OYS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matti E Hillbom, MD, PhD</last_name>
      <phone>358-8-315-4518</phone>
      <email>matti.hillbom@oulu.fi</email>
    </contact>
    <contact_backup>
      <last_name>Juha T Huhtakangas, MD</last_name>
      <phone>358-8-315-4032</phone>
      <email>juha.huhtakangas@ppshp.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Juha T Huhtakangas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tarja T Haapaniemi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sami T Tetri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michaela Bode, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pertti Saloheimo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eeva-Riitta Savolainen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <last_update_submitted>July 1, 2010</last_update_submitted>
  <last_update_submitted_qc>July 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Oulu University Hospital (Matti Hillbom)</name_title>
    <organization>Oulu University Hospital</organization>
  </responsible_party>
  <keyword>Intracerebral hemorrhage</keyword>
  <keyword>Hematoma enlargement</keyword>
  <keyword>Antiplatelet agent</keyword>
  <keyword>Platelet transfusion</keyword>
  <keyword>Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

